Astec LifeSciences' Stock Price up by More Than 12% Today, After Rs 250 Crore Rights Issue Announcement
By Ankur Chandra | Published at: Jun 24, 2025 05:34 PM IST
Mumbai, June 24, 2025: Astec LifeSciences Ltd’s (NSE: ASTEC, BSE: 533138) share rose by 12.62% (₹861.05 per share at 02:00 PM) after the Board of Directors approved a Rights Issue of equity shares worth up to ₹250 crores. The move is viewed as a sign of confidence and capital expansion, and investors expect strong long-term growth and profitability.
The issue will aim to reduce debt levels and execute the company’s expansion plans. The overall sentiment towards the agrochemical/pharma sector remains stable.
Board Approves Capital Raise via Rights Issue
The Board, in its meeting held on June 24, approved raising capital by issuing fully paid-up equity shares of ₹10 face value each for an aggregate amount not exceeding ₹250 crore. The Rights Issue will be offered to existing shareholders on a record date and will be announced later.
“The issue price, rights entitlement ratio, record date, and payment terms will be decided in due course by the Board or a duly authorized committee,” the company stated in its exchange filing.
This capital infusion will be made per SEBI (ICDR) Regulations, 2018 and the Companies Act, 2013.
Key Regulatory Details
| Regulation Invoked | SEBI (LODR) Regulation 30 |
|---|---|
| Purpose | Rights Issue Approval |
| Amount | Up to ₹250 crore |
| Instrument | Fully paid equity shares |
| Face Value | ₹10 per share |
| Status | Awaiting detailed terms |
Stock Performance and Market Snapshot
Astec’s stock opened at ₹764.50 and touched a high of ₹818.85 today, before settling at ₹818.40 as of 11:40 AM IST. This represents a 7.04% increase from the previous close of ₹764.55.
| Parameter | Value |
|---|---|
| Last Traded Price | ₹818.40 |
| Day’s High / Low | ₹818.85 / ₹764.50 |
| Traded Volume (Lakhs) | 0.22 |
| Market Cap (₹ Cr.) | 1,605.02 |
| 52-Week High / Low | ₹1,474.40 / ₹634.60 |
| Free Float Market Cap (₹ Cr.) | 520.42 |
| Price Band (%) | 20 |
Despite being loss-making over the last eight quarters, Astec’s renewed focus on capital raising appears to have revived investor confidence.
What’s Next?
The Board has yet to finalise critical details such as:
- Rights entitlement ratio
- Issue price
- Record date
- Payment schedule
These parameters will be announced shortly and are expected to drive further investor interest.
About the Company
Astec LifeSciences Limited is a listed agrochemical company that manufactures pesticides and other agri-inputs. The stock is actively traded and was listed on the BSE and NSE on November 25, 2009. It operates as part of the Godrej Group and serves both domestic and international markets in the crop protection space.
REF: https://nsearchives.nseindia.com/corporate/ASTEC_24062025113408_BSENSEBMOUTCOME24062025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
